February 12, 2018 / 1:20 PM / 2 months ago

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

Feb 12 (Reuters) - Opiant Pharmaceuticals Inc:

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003

* OPIANT PHARMACEUTICALS INC - ANTICIPATES TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020

* OPIANT PHARMACEUTICALS INC - ANTICIPATE SUBMITTING AN NDA FOR OPNT003 IN 2020

* OPIANT - HAS FULL COMMERCIAL RIGHTS TO OPNT003; SUBMITTED GRANT APPLICATION TO NATIONAL INSTITUTES OF HEALTH TO FUND DEVELOPMENT TO NDA READY STAGE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below